Prevacid, Zyvox, Valcyte Paragraph IV Certifications Filed
This article was originally published in The Pink Sheet Daily
The first ANDA with a Paragraph IV certification for TAP's heartburn and GERD therapy Prevacid was filed in December, FDA's list of certification filings indicates
You may also be interested in...
TAP plans to continue sale of prescription lansoprazole “at least” until the compound patent expires.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.